第5章 非侵襲產前檢查:比較檢驗分析

第6章 非侵襲產前檢查市場上契約種類

合作協議

聯盟契約

銷售協定契約

授權協定契約

壟斷契約

M&A契約

創業投資投資契約

第7章 非侵襲產前檢查市場的促進因素

唐氏症兒的高發病率

第8章 非侵襲產前檢查市場上的課題

法規指南、倫理的門檻

圖表一覽

目錄

The development of the non-invasive prenatal test (NIPT) has transformed the prenatal testing market. NIPT has the potential to drastically change how pregnancies are managed. Non-invasive prenatal genetic testing (NIPT) has been commercially available since 2011 and has been rapidly adopted in the US and in parts of Europe. Recently, companies have also started marketing NIPT in low- and middle-income countries (LMICs).

Sequenom, Inc. was the first company that offered its proprietary non-invasive prenatal test MaterniT21 PLUS for detecting fetal chromosomal aneuploidies in pregnant women in October 2011, and since then it is leading the market. Sequenom, Inc. accounts for XXX% of the total revenue generated in the global NIPT market, followed by Verifi test with a market share of XXX% in the year 2013. Non invasive prenatal testing market will touch XX Billion marks by the year 2019 and it is expected to show substantial growth of more than 150% from 2014 to 2019.

Prenatal diagnosis gives parents and medical professionals a chance to manage high-risk pregnancies and provides advanced warning of any possible birth complications, which increases the chances of having a healthy baby. The increase in the maternal age along with rising fetal abnormalities and advancement in the realm of non-invasive prenatal testing method will drive the market for NIPT.